CNXC Stock Analysis: Concentrix | NASDAQ
Information Technology Services | NASDAQ, USA | Market Cap: 1.521m USD | 12M Return: -42.6% | US20602D1019 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 54.6M
EPS Trend: -64.3%
Qual. Beats: 1
Rev. Trend: 83.3%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Concentrix Corporation (NASDAQ: CNXC) is a global provider of integrated customer experience (CX) solutions, offering services such as CX process optimization, technology and design engineering, front- and back-office automation, analytics, and business transformation. The company serves a wide range of industry verticals, including technology and consumer electronics, retail, travel and e-commerce, communications and media, banking/financial services/insurance (BFSI), and healthcare. Its offerings span customer lifecycle management, digital transformation, enterprise data analytics, and AI-driven engagement tools-particularly GenAI and agentic AI assistants-covering self-service, language translation, internal chatbots, voice-of-customer feedback, and back-office support.
Founded in 2004 and headquartered in Newark, California, Concentrix operates in the Data Processing & Outsourced Services sub-industry within the Industrials sector. The companys business model centers on long-term, often multi-year outsourcing contracts that bundle technology platforms with global delivery capabilities, allowing clients to scale customer support and digital operations efficiently. Concentrix went public in late 2020 and is classified as a small-cap stock.
- AI automation adoption cuts client headcount demand
- BFSI and tech verticals drive segment revenue mix
- Margin pressure from wage inflation in offshore delivery centers
| Net Income: -2.39b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.64 > 1.0 |
| NWC/Revenue: 5.48% < 20% (prev 11.61%; Δ -6.13% < -1%) |
| CFO/TA 0.08 > 3% & CFO 743.7m > Net Income -2.39b |
| Net Debt (4.78b) to EBITDA (99.1m): 48.20 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.9m) vs 12m ago -3.90% < -2% |
| Gross Margin: 32.45% > 18% (prev 35.28%; Δ -2.84% > 0.5%) |
| Asset Turnover: 92.01% > 50% (prev 78.33%; Δ 13.68% > 0%) |
| Interest Coverage Ratio: -1.98 > 6 (EBIT TTM -551.0m / Interest Expense TTM 278.2m) |
| A: 0.06 (Total Current Assets 2.92b - Total Current Liabilities 2.37b) / Total Assets 9.26b |
| B: -0.13 (Retained Earnings -1.16b / Total Assets 9.26b) |
| C: -0.05 (EBIT TTM -551.0m / Avg Total Assets 10.8b) |
| D: 0.24 (Book Value of Equity 1.77b / Total Liabilities 7.49b) |
| Altman-Z'' = -0.11 = B |
| DSRI: 0.94 (Receivables 1.97b/2.05b, Revenue 9.97b/9.72b) |
| GMI: 1.09 (GM 35.28% / 32.45%) |
| AQI: 0.75 (AQ_t 0.52 / AQ_t-1 0.69) |
| SGI: 1.03 (Revenue 9.97b / 9.72b) |
| TATA: -0.34 (NI -2.39b - CFO 743.7m) / TA 9.26b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of October 08, 2026, the stock is trading at USD 26.16 with a total of 1,395,629 shares traded. Over the past week, the price has changed by +4.85%, over one month by -7.46%, over three months by +16.40% and over the past year by -42.59%.
Current recommended Stop Loss: 23.30 (which is 10.9% or 1.3 ATR below the current price).
Concentrix has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CNXC.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 36 | 37.6% |
P/E Forward = 2.6846
P/S = 0.1521
P/B = 0.6829
P/EG = 0.3835
Revenue TTM = 9.97b USD
EBIT TTM = -551.0m USD
EBITDA TTM = 99.1m USD
Long Term Debt = 4.57b USD (from longTermDebt, last fiscal year)
Short Term Debt = 450.0m USD (from shortTermDebt, last quarter)
Debt = 5.02b USD (corrected: LT Debt 4.57b + ST Debt 450.0m)
Net Debt = 4.78b USD (calculated: Debt 5.02b - CCE 244.7m)
Enterprise Value = 6.30b USD (1.52b + Debt 5.02b - CCE 244.7m)
Interest Coverage Ratio = -1.98 (Ebit TTM -551.0m / Interest Expense TTM 278.2m)
EV/FCF = 12.27x (Enterprise Value 6.30b / FCF TTM 513.5m)
FCF Yield = 8.15% (FCF TTM 513.5m / Enterprise Value 6.30b)
FCF Margin = 5.15% (FCF TTM 513.5m / Revenue TTM 9.97b)
Net Margin = -23.98% (Net Income TTM -2.39b / Revenue TTM 9.97b)
Gross Margin = 32.45% ((Revenue TTM 9.97b - Cost of Revenue TTM 6.73b) / Revenue TTM)
Gross Margin QoQ = 34.60% (prev 33.44%)
Tobins Q-Ratio = 0.68 (Enterprise Value 6.30b / Total Assets 9.26b)
Interest Expense / Debt = 5.54% (Interest Expense 278.2m / Debt 5.02b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -435.3m (EBIT -551.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 2.92b / Total Current Liabilities 2.37b)
Debt / Equity = 2.84 (Debt 5.02b / totalStockholderEquity, last quarter 1.77b)
Debt / EBITDA = 48.20 (Net Debt 4.78b / EBITDA 99.1m)
Debt / FCF = 9.30 (Net Debt 4.78b / FCF TTM 513.5m)
Total Stockholder Equity = 2.50b (last 4 quarters mean from totalStockholderEquity)
RoA = -22.06% (Net Income -2.39b / Total Assets 9.26b)
RoE = -95.60% (Net Income TTM -2.39b / Total Stockholder Equity 2.50b)
RoCE = -7.79% (EBIT -551.0m / Capital Employed (Equity 2.50b + L.T.Debt 4.57b))
RoIC = -6.13% (negative operating profit) (NOPAT -435.3m / Invested Capital 7.10b)
WACC = 5.57% (E(1.52b)/V(6.54b) * Re(9.52%) + D(5.02b)/V(6.54b) * Rd(5.54%) * (1-Tc(0.21)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.81 | Cagr: -3.07%
[DCF] Terminal Value 76.19% ; FCFF base≈502.1m ; Y1≈528.8m ; Y5≈616.3m
[DCF] Fair Price = 77.33 (EV 9.49b - Net Debt 4.78b = Equity 4.71b / Shares 60.9m; r=8.35% [WACC [floored]]; 5y FCF grow 5.90% → 2.50% )
EPS Correlation: -64.33 | EPS CAGR: -2.34% | SUE: 1.34 | # QB: 1
Revenue Correlation: 83.28 | Revenue CAGR: 10.43% | SUE: -1.70 | # QB: -2
EPS current Quarter (2027-02-28): EPS=2.90 | Chg30d=+2.05% | Revisions=-50% | Analysts=2
EPS current Year (2026-11-30): EPS=11.08 | Chg30d=-1.07% | Revisions=-50% | GrowthEPS=-1.2% | GrowthRev=+0.3%
EPS next Year (2027-11-30): EPS=11.76 | Chg30d=-1.11% | Revisions=-50% | GrowthEPS=+6.1% | GrowthRev=-0.4%
[Analyst] Revisions Ratio: -75% (up=0, down=9)